top of page

NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts Efficacy of Immunotherapy

Tucson, AZ, September 09, 2021 --(PR.com)-- NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive preclinical data showing that its lead drug, NanO2TM, boosts the efficacy of immunotherapy in a mouse model of triple negative breast cancer. Triple negative breast cancer (TNBC) is a particularly deadly form of breast cancer affecting about 50,000 patients each year in the US.

Recent Posts

See All

NuvOx Pharma Announces Issuance of a New Patent

Tucson, AZ,  January 2, 2024 - NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic.” Evan Unger, MD, President and CE

NuvOx Announces Contract to Support NOVEL Trial

Tucson, AZ, USA, October 31, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role,

Comments


bottom of page